eNOS Polyclonal Antibody, RBITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-20608R-RBITC |
| Product Name | eNOS Polyclonal Antibody, RBITC Conjugated |
| Applications | WB, IF(ICC) |
| Reactivity | Human, Rat |
| Predicted Reactivity | Mouse, Cow, Sheep, Pig, Rabbit |
| Specifications | |
| Conjugation | RBITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human eNOS/NOS-3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4846 |
| Swiss Prot | P29474 |
| Synonyms | NOS-3; cNOS; eNOS; Constitutive NOS; EC NOS; ecNOS; Endothelial nitric oxidase synthase; Endothelial nitric oxide synthase; Endothelial nitric oxide synthase 3; Endothelial NOS; Nitric oxide synthase 3 (endothelial cell); Nitric oxide synthase 3; Nitric oxide synthase 3 endothelial cell; Nitric oxide synthase endothelial; nitric oxide synthase, endothelial; NOS 3; NOS III; NOS type III; NOS3; NOSIII; NOS3_HUMAN. |
| Background | Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1. |
| Application Dilution | |
| WB | |
| IF(ICC) | |
Powered by Bioz